Stock screener

GYRE

Conviction 20HealthcareScan · Thu, Jun 25, 2026
GYRE$6.21-4.17%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 94.27K
Mar 26Apr 14May 1May 19Jun 8Jun 25
GYRE THERAPEUTICS, INC.PHARMACEUTICAL PREPARATIONSwww.gyretx.com
Price6.21
Change-4.17%
Gap+0.77%
Rel volume2.60×
Avg volume98.81K
Avg $ vol596.78K
SMA 206.01
SMA 506.74
SMA 2007.46
Price vs 50-7.91%
Price vs 200-16.76%
MA stackbearish
50/200 cross
Supertrenddown · 6.54
RSI (14)49
MACD hist0.09
MACD cross
Stoch %K / %D50 / 61
ADX (14)22
+DI / −DI27 / 16
RSI divergence
MACD divergence
ATR %+5.25%
ADR %5.28%
52w high8.87
52w low5.56
From 52w high-29.99%
Above 52w low+11.69%
New 52w highNo
SqueezeOff
Bollinger width14.71%
%B0.72
Donchian pos61.83%
Donchian high6.69
Donchian low5.44
AVWAP (52w high)7.41
vs AVWAP high-16.14%
AVWAP (52w low)6.10
vs AVWAP low+1.73%
OBV trendFlat
Chaikin MF (20)-0.21
Today vs 20d2.60×
Avg vol (14d)94.27K
Avg vol (20d)98.81K
Avg $ vol (20d)596.78K
Market cap602.55M
RS 3m (vs SPY)-18.89%
RS 6m (vs SPY)-16.85%
RS line new highNo
Trend template0/8
Technical rank33.0
1 week+2.14%
1 month+4.55%
3 months-13.51%
6 months-13.63%
1 year-18.40%
YTD-8.81%
P/E60.99
P/B5.95
P/S5.17
P/FCF-3347.48
EPS0.0200
Div yield
ROE9.75%
ROA6.10%
Debt/Eq0.01
Current4.64
EV/EBITDA40.50
Gross margin87.38%
Net margin8.47%
Rev growth10.24%
EPS growth-44.80%
Price target
Target upside
Analyst rating
Institutional
Ent. value565.66M
Revenue22.52M
Net income-9.86M
Gross profit28.94M
Free cash flow-180K
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out97.03M
Employees618
ListedTue, Oct 31, 2023
Free float17.84M
Float %18.4%
Short interest1.67M
Days to cover17.6d
Short volume61.5%
Squeeze score73 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction20 / 100
Pattern quality
Tech rank33.0 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance7.38
Support5.56
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GYRE

All disclosures →
No recent disclosed trades by Congress in GYRE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GYRE · 4 buys · 6 sells

InsiderSideShares
Ye Weiguo
Chief Operating Officer · Common Stock · 2026-06-18
Sell3K
Ye Weiguo
Chief Operating Officer · Common Stock · 2026-06-18
Exercise3K
Ye Weiguo
Chief Operating Officer · Stock Option (Right to Buy) · 2026-06-18
Exercise3K
Ye Weiguo
Chief Operating Officer · Common Stock · 2026-06-10
Exercise5K
Ye Weiguo
Chief Operating Officer · Common Stock · 2026-06-10
Sell5K
Ye Weiguo
Chief Operating Officer · Stock Option (Right to Buy) · 2026-06-10
Exercise5K
Ye Weiguo
Chief Operating Officer · Common Stock · 2026-06-09
Exercise3K
Ye Weiguo
Chief Operating Officer · Common Stock · 2026-06-09
Sell3K
Ye Weiguo
Chief Operating Officer · Stock Option (Right to Buy) · 2026-06-09
Exercise3K
Bergmann Joshua Benjamin
GC and Corporate Secretary · Stock Option (Right to Buy) · 2026-06-08
Grant50K

SEC filings

EDGAR filings in GYRE · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.